1
|
Matsuda R, Hasegawa M, Tamamoto T, Inooka N, Morimoto T, Maeoka R, Nakazawa T, Ochi T, Miyasaka T, Hontsu S, Yamaki K, Miura S, Yamada S, Nishimura F, Nakagawa I, Park YS, Nakase H. Clinical Results and Hematologic Predictors of Linear Accelerator-Based Stereotactic Radiosurgery or Fractionated Stereotactic Radiotherapy for Brain Metastasis in Patients Aged 75 Years or Older: A Retrospective Study. World Neurosurg 2024; 183:e944-e952. [PMID: 38244685 DOI: 10.1016/j.wneu.2024.01.069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2023] [Revised: 01/11/2024] [Accepted: 01/12/2024] [Indexed: 01/22/2024]
Abstract
OBJECTIVE This study aimed to evaluate prognostic factors including pre-radiosurgical blood count in elderly patients (EPs) with brain metastasis (BM) who were treated using linear accelerator (LINAC)-based stereotactic radiosurgery (SRS) and fractionated stereotactic radiotherapy (fSRT) with a micro-multileaf collimator. METHODS Between January 2011 and November 2021, 101 consecutive EPs with BM were treated by LINAC-based SRS or fSRT using LINAC with a micro-multileaf collimator. EPs were defined as patients aged ≥75 years. RESULTS The tumors originated from the lungs (n = 90; 89.1%), colon (n = 2; 2.0%), and others (n = 9; 8.8%) in these EPs. The median pretreatment Karnofsky Performance Status was 80 (range, 40-100). The median follow-up time was 10 months (range, 0-76), as was the median survival. The 6-month, 1-year, and 2-year survival in the EP group was 58.3%, 43.2%, and 28.5%, respectively. Freedom from local failure at 6 months and 1 and 2 years was 97%, 95%, and 91.5%, respectively. Freedom from distant failure at 6 months and 1 and 2 years in EPs was 70.6%, 59.4%, and 54.2%, respectively. A high neutrophil/lymphocyte ratio >5.33 was an unfavorable predictor of prognosis for EPs with BMs treated with SRS and fSRT (P < 0.001). In the EPs, the prognostic factors associated with prolonged survival in the Cox proportional hazards model were being female and a good pretreatment Karnofsky Performance Status. CONCLUSIONS The findings of our study highlight the efficacy of LINAC-based SRS and fSRT with a micro-multileaf collimator in the treatment of EPs with BMs. Neutrophil/lymphocyte ratio can be an important factor in treatment decisions for EPs with BMs.
Collapse
Affiliation(s)
- Ryosuke Matsuda
- Department of Neurosurgery, Nara Medical University, Kashihara, Nara, Japan.
| | - Masatoshi Hasegawa
- Department of Radiation Oncology, Nara Medical University, Kashihara, Nara, Japan
| | - Tetsuro Tamamoto
- Department of Radiation Oncology, Nara Medical University, Kashihara, Nara, Japan; Department of Medical Informatics, Nara Medical University Hospital, Kashihara, Nara, Japan
| | - Nobuyoshi Inooka
- Department of Radiation Oncology, Nara Medical University, Kashihara, Nara, Japan
| | - Takayuki Morimoto
- Department of Neurosurgery, Nara Medical University, Kashihara, Nara, Japan
| | - Ryosuke Maeoka
- Department of Neurosurgery, Nara Medical University, Kashihara, Nara, Japan
| | - Tsutomu Nakazawa
- Department of Neurosurgery, Nara Medical University, Kashihara, Nara, Japan
| | - Tomoko Ochi
- Department of Respiratory Medicine, Nara Medical University, Kashihara, Nara, Japan
| | - Toshiteru Miyasaka
- Department of Respiratory Medicine, Nara Medical University, Kashihara, Nara, Japan
| | - Shigeto Hontsu
- Department of Respiratory Medicine, Nara Medical University, Kashihara, Nara, Japan
| | - Kaori Yamaki
- Department of Radiation Oncology, Nara Medical University, Kashihara, Nara, Japan
| | - Sachiko Miura
- Department of Radiation Oncology, Nara Medical University, Kashihara, Nara, Japan
| | - Shuichi Yamada
- Department of Neurosurgery, Nara Medical University, Kashihara, Nara, Japan
| | - Fumihiko Nishimura
- Department of Neurosurgery, Nara Medical University, Kashihara, Nara, Japan
| | - Ichiro Nakagawa
- Department of Neurosurgery, Nara Medical University, Kashihara, Nara, Japan
| | - Young-Soo Park
- Department of Neurosurgery, Nara Medical University, Kashihara, Nara, Japan
| | - Hiroyuki Nakase
- Department of Neurosurgery, Nara Medical University, Kashihara, Nara, Japan
| |
Collapse
|
2
|
Kuyama S, Yoshioka H, Kaneda H, Kataoka Y, Miura S, Katakami N, Yamanaka Y, Tamiya A, Yamada T, Yokoyama T, Hara S, Tanaka H, Fujisaka Y, Nakamura A, Azuma K, Namba M, Hata A, Sawa K, Ishikawa H, Kurata T. 330P A real-world multi-center prospective observational study of atezolizumab (Atezo) + bevacizumab (Bev) + carboplatin (CBDCA) + paclitaxel (PTX) (ABCP) in patients (pts) with advanced EGFR-mutated (EGFRm) NSCLC after EGFR-TKIs failure. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022] Open
|
3
|
Kaneda H, Hazama D, Kodama H, Miyazaki A, Azuma K, Kawashima Y, Sato Y, Ito K, Shiraishi Y, Miura K, Takahama T, Oizumi S, Namba Y, Ikeda S, Miura S, Tachihara M. 333P Efficacy and safety of immune checkpoint inhibitors alone or combined with chemotherapy in pulmonary sarcomatoid carcinoma. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022] Open
|
4
|
Yamaguchi H, Wakuda K, Fukuda M, Kenmotsu H, Ito K, Tsuchiya-Kawano Y, Tanaka K, Harada T, Nakatani Y, Miura S, Yokoyama T, Nakamura T, Izumi M, Nakamura A, Ikeda S, Takayama K, Yoshimura K, Nakagawa K, Yamamoto N, Sugio K. 990P Osimertinib for RT-naïve CNS metastasis of EGFR mutation-positive NSCLC: Phase II OCEAN study (LOGIK 1603/WJOG 9116L), part of the first-line cohort. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
5
|
Miura S, Abady Z, Pollok F, Ma M, Kinoshita K, Fogarty S, Maguire P, Daugherty B, Lederman S, Pierson R. TNX-1500, an Fc-Modified Anti-CD154 Antibody, Prolongs Nonhuman Primate Cardiac Allograft Survival. J Heart Lung Transplant 2022. [DOI: 10.1016/j.healun.2022.01.348] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
6
|
Calhoun A, Connolly M, Pollok F, Burdof L, Ma M, Miura S, Eyestone W, Phelps C, Ayares D, Azimzadeh A, Pierson R. Ischemia Minimization Reduces Cardiac Xenograft Injury. J Heart Lung Transplant 2022. [DOI: 10.1016/j.healun.2022.01.749] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
7
|
Fukumoto KI, Miura S, Yamazaki M, Satou M. Effect of Temperature History on the Irradiation Behavior of Vanadium Alloy Irradiated with the MARICO-II Rig in a Fast Reactor, JOYO. Nuclear Materials and Energy 2022. [DOI: 10.1016/j.nme.2022.101153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
8
|
Matsuda R, Hasegawa M, Tamamoto T, Ochi T, Miyasaka T, Inooka N, Hontsu S, Miura S, Takeshima Y, Tamura K, Yamada S, Nishimura F, Nakagawa I, Motoyama Y, Park YS, Nakase H. Linac-based stereotactic radiosurgery and fractionated stereotactic radiotherapy with a micro-multileaf collimator for brain metastasis in the primary motor cortex. J Radiat Res 2022; 63:63-70. [PMID: 34927204 PMCID: PMC8776695 DOI: 10.1093/jrr/rrab111] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/09/2021] [Revised: 05/04/2021] [Indexed: 05/05/2023]
Abstract
This study aimed to assess the clinical outcomes of linear accelerators (linac)-based, stereotactic radiosurgery (SRS) and fractionated stereotactic radiotherapy (fSRT) with a micro-multileaf collimator for brain metastasis in the primary motor cortex (BMPMC). Thirty-five consecutive patients with BMPMC who were treated by linac-based SRS or fSRT between January 2012 and March 2020 were analyzed. BMPMC was defined as a tumor located in the precentral gyrus on gadolinium-enhanced magnetic resonance imaging (MRI) and T2-weghted imaging (T2WI). In total, 35 patients with 37 metastases were analyzed. The median follow-up time was 13 (range: 1-97) months. The tumor volume was 0.05-26.5 (median: 0.62) cm3. All patients were treated with SRS or fSRT using 35 Gy with 7 Gy per fraction daily. The median survival time (MST) was 16.9 months. The pretreatment KPS and RPA class significantly differed in terms of MST on the log-rank tests. Seven symptomatic patients had hemiparesis before SRS or fSRT. All symptomatic patients, except one with facial paresis and one who died within 3 months, experienced improvement at a 3 month follow-up. None of the patients presented with persistent radiation injury at the final follow-up. Two patients presented with grade 3 radiation-related central nervous system necrosis, which was assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. In BMPMC, SRS and fSRT had good tumor control and did not cause serious complications. Therefore, they are suitable treatment options with an acceptable safety profile.
Collapse
Affiliation(s)
- Ryosuke Matsuda
- Corresponding author. Department of Neurosurgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan Tel: +81-744-22-3051 Fax: +81-744-29-0818
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Matsuda R, Morimoto T, Tamamoto T, Inooka N, Ochi T, Miyasaka T, Hontsu S, Yamaki K, Miura S, Takeshima Y, Tamura K, Yamada S, Nishimura F, Nakagawa I, Motoyama Y, Park YS, Hasegawa M, Nakase H. Salvage Surgical Resection after Linac-Based Stereotactic Radiosurgery for Newly Diagnosed Brain Metastasis. Curr Oncol 2021; 28:5255-5265. [PMID: 34940078 PMCID: PMC8699906 DOI: 10.3390/curroncol28060439] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2021] [Revised: 12/01/2021] [Accepted: 12/06/2021] [Indexed: 11/16/2022] Open
Abstract
Background: This study aimed to assess the clinical outcomes of salvage surgical resection (SSR) after stereotactic radiosurgery and fractionated stereotactic radiotherapy (SRS/fSRT) for newly diagnosed brain metastasis. Methods: Between November 2009 and May 2020, 318 consecutive patients with 1114 brain metastases were treated with SRS/fSRT for newly diagnosed brain metastasis at our hospital. During this study period, 21 of 318 patients (6.6%) and 21 of 1114 brain metastases (1.9%) went on to receive SSR after SRS/fSRT. Three patients underwent multiple surgical resections. Twenty-one consecutive patients underwent twenty-four SSRs. Results: The median time from initial SRS/fSRT to SSR was 14 months (range: 2–96 months). The median follow-up after SSR was 17 months (range: 2–78 months). The range of tumor volume at initial SRS/fSRT was 0.12–21.46 cm3 (median: 1.02 cm3). Histopathological diagnosis after SSR was recurrence in 15 cases, and radiation necrosis (RN) or cyst formation in 6 cases. The time from SRS/fSRT to SSR was shorter in the recurrence than in the RNs and cyst formation, but these differences did not reach statistical significance (p = 0.067). The median survival time from SSR and from initial SRS/fSRT was 17 and 74 months, respectively. The cases with recurrence had a shorter survival time from initial SRS/fSRT than those without recurrence (p = 0.061). Conclusions: The patients treated with SRS/fSRT for brain metastasis need long-term follow-up. SSR is a safe and effective treatment for the recurrence, RN, and cyst formation after SRS/fSRT for brain metastasis.
Collapse
Affiliation(s)
- Ryosuke Matsuda
- Department of Neurosurgery, Nara Medical University, Kashihara 634-8521, Japan; (T.M.); (Y.T.); (K.T.); (S.Y.); (F.N.); (I.N.); (Y.M.); (Y.-S.P.); (H.N.)
- Correspondence: ; Tel.: +81-744-22-3051
| | - Takayuki Morimoto
- Department of Neurosurgery, Nara Medical University, Kashihara 634-8521, Japan; (T.M.); (Y.T.); (K.T.); (S.Y.); (F.N.); (I.N.); (Y.M.); (Y.-S.P.); (H.N.)
| | - Tetsuro Tamamoto
- Department of Radiation Oncology, Nara Medical University, Kashihara 634-8521, Japan; (T.T.); (N.I.); (K.Y.); (S.M.); (M.H.)
- Department of Medical Informatics, Nara Medical University Hospital, Kashihara 634-8522, Japan
| | - Nobuyoshi Inooka
- Department of Radiation Oncology, Nara Medical University, Kashihara 634-8521, Japan; (T.T.); (N.I.); (K.Y.); (S.M.); (M.H.)
| | - Tomoko Ochi
- Department of Radiology, Nara Medical University Hospital, Kashihara 634-8522, Japan; (T.O.); (T.M.)
| | - Toshiteru Miyasaka
- Department of Radiology, Nara Medical University Hospital, Kashihara 634-8522, Japan; (T.O.); (T.M.)
| | - Shigeto Hontsu
- Department of Respiratory Medicine, Nara Medical University Hospital, Kashihara 634-8522, Japan;
| | - Kaori Yamaki
- Department of Radiation Oncology, Nara Medical University, Kashihara 634-8521, Japan; (T.T.); (N.I.); (K.Y.); (S.M.); (M.H.)
| | - Sachiko Miura
- Department of Radiation Oncology, Nara Medical University, Kashihara 634-8521, Japan; (T.T.); (N.I.); (K.Y.); (S.M.); (M.H.)
| | - Yasuhiro Takeshima
- Department of Neurosurgery, Nara Medical University, Kashihara 634-8521, Japan; (T.M.); (Y.T.); (K.T.); (S.Y.); (F.N.); (I.N.); (Y.M.); (Y.-S.P.); (H.N.)
| | - Kentaro Tamura
- Department of Neurosurgery, Nara Medical University, Kashihara 634-8521, Japan; (T.M.); (Y.T.); (K.T.); (S.Y.); (F.N.); (I.N.); (Y.M.); (Y.-S.P.); (H.N.)
| | - Shuichi Yamada
- Department of Neurosurgery, Nara Medical University, Kashihara 634-8521, Japan; (T.M.); (Y.T.); (K.T.); (S.Y.); (F.N.); (I.N.); (Y.M.); (Y.-S.P.); (H.N.)
| | - Fumihiko Nishimura
- Department of Neurosurgery, Nara Medical University, Kashihara 634-8521, Japan; (T.M.); (Y.T.); (K.T.); (S.Y.); (F.N.); (I.N.); (Y.M.); (Y.-S.P.); (H.N.)
| | - Ichiro Nakagawa
- Department of Neurosurgery, Nara Medical University, Kashihara 634-8521, Japan; (T.M.); (Y.T.); (K.T.); (S.Y.); (F.N.); (I.N.); (Y.M.); (Y.-S.P.); (H.N.)
| | - Yasushi Motoyama
- Department of Neurosurgery, Nara Medical University, Kashihara 634-8521, Japan; (T.M.); (Y.T.); (K.T.); (S.Y.); (F.N.); (I.N.); (Y.M.); (Y.-S.P.); (H.N.)
| | - Young-Soo Park
- Department of Neurosurgery, Nara Medical University, Kashihara 634-8521, Japan; (T.M.); (Y.T.); (K.T.); (S.Y.); (F.N.); (I.N.); (Y.M.); (Y.-S.P.); (H.N.)
| | - Masatoshi Hasegawa
- Department of Radiation Oncology, Nara Medical University, Kashihara 634-8521, Japan; (T.T.); (N.I.); (K.Y.); (S.M.); (M.H.)
| | - Hiroyuki Nakase
- Department of Neurosurgery, Nara Medical University, Kashihara 634-8521, Japan; (T.M.); (Y.T.); (K.T.); (S.Y.); (F.N.); (I.N.); (Y.M.); (Y.-S.P.); (H.N.)
| |
Collapse
|
10
|
Popat S, Jung H, Lee S, Hochmair M, Lee S, Escriu C, Lee M, Migliorino M, Lee Y, Girard N, Daoud H, Märten A, Miura S. P51.05 Sequential Afatinib and Osimertinib in Patients With Advanced EGFRm+ NSCLC and Acquired T790M: The Real-World UpSwinG study. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.542] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
11
|
Miura S, Azuma K, Yoshioka H, Teraoka S, Ishii H, Koyama K, Kibata K, Ozawa Y, Tokito T, Koh Y, Shimokawa T, Kurata T, Yamamoto N, Tanaka H. MA02.05 A Phase I Study of Afatinib in Combination With Osimertinib in Patients After Failure of Prior Osimertinib. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
12
|
Kenmotsu H, Wakuda K, Mori K, Kato T, Sugawara S, Kirita K, Okamoto I, Azuma K, Nishino K, Teraoka S, Koyama R, Masuda K, Hayashi H, Toyozawa R, Miura S, Sato Y, Nakagawa K, Yamamoto N, Takahashi T. LBA44 Primary results of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations: WJOG9717L study. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.2123] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
13
|
Miura S, Hsia TC, Hung JY, Jung H, Shih JY, Park CK, Lee S, Okamoto T, Ahn H, Lee Y, Sato Y, Lee S, Mascaux C, Daoud H, Märten A, Popat S. 1217P EGFR TKIs in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1822] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
14
|
Yang JH, Schuler M, Popat S, Miura S, Park K, Passaro A, de Marinis F, Solca F, Märten A, Kim E. 1212P Afatinib for the treatment of NSCLC with uncommon EGFR mutations: An updated database of 1023 cases. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1817] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
15
|
Miura S, Hsia TC, Hung JY, Jung H, Shih JY, Yang TY, Park CK, Lee S, Okamoto T, Ahn H, Lee Y, Sato Y, Lee S, Mascaux C, Daoud H, Märten A, Popat S. 145P UpSwinG: Real-world, non-interventional cohort study on TKI activity in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC with uncommon mutations. J Thorac Oncol 2021. [DOI: 10.1016/s1556-0864(21)01987-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
16
|
Nakamura A, Yoneshima Y, Morita S, Ando M, Iwasawa S, Yoshioka H, Goto Y, Takeshita M, Harada T, Hirano K, Oguri T, Kondo M, Miura S, Hosomi Y, Kato T, Kubo T, Kishimoto J, Yamamoto N, Nakanishi Y, Okamoto I. OA03.05 Phase III Study Comparing Nab-Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
17
|
Chih-Hsin Yang J, Schuler M, Popat S, Miura S, Heeke S, Passaro A, de Marinis F, Park K, Kim E. MO01.36 Afatinib in Asian and Non-Asian Patients (pts) with EGFR Mutation-Positive (EGFRm+) NSCLC Harboring Major Uncommon Mutations. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2020.10.141] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
18
|
Miura S, Märten A, Popat S. 420TiP UpSwinG: Real-world study of TKI activity in patients with EGFR mutation-positive (EGFRm+) NSCLC with uncommon mutations, and sequencing of afatinib followed by osimertinib. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.466] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
19
|
Yang JH, Schuler M, Popat S, Miura S, Heeke S, Passaro A, de Marinis F, Park K, Kim E. 395P Afatinib in Asian and non-Asian patients (pts) with EGFR mutation positive (EGFRm+) NSCLC harboring major uncommon mutations. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
20
|
Kato Y, Iwata A, Miura S. Impact of visit-to-visit variability in blood pressure on coronary plaque as assessed by integrated backscatter intravascular ultrasound. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2458] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Visit-to-visit variability (VVV) in blood pressure (BP) has been reported to be a strong predictor of cardiovascular disease. However, the association of VVV in BP and coronary plaque composition has not been fully elucidated.
Purpose
The aim of this study was to examine the relationship between VVV in BP and the tissue characteristics of coronary plaques as assessed by integrated backscatter (IB) intravascular ultrasound (IVUS) in patients with coronary artery disease (CAD).
Methods
One hundred-two consecutive patients with CAD who underwent percutaneous coronary intervention (PCI) using IVUS, and who had at least six clinic visits a year before PCI were included. We measured systolic and diastolic BP (SBP and DBP) at each visit and determined VVV in BP expressed as the standard deviation of the average BP. Gray-scale and IB IVUS examinations were performed for the culprit lesion of a coronary artery just before PCI.
Results
There were no significant associations between the average SBP or DBP and various IVUS parameters. However, VVV in SBP was positively correlated with both the percentage of atheroma volume (PAV) (r=0.227, p=0.023) and percentage of lipid volume (PLV) (r=0.532, p<0.001). VVV in DBP was positively correlated with PLV (r=0.243, p=0.014), while there was no significant correlation between VVV in DBP and PAV. A multiple regression analysis showed that VVV in SBP was independently associated with PAV (p=0.036) and PLV (p<0.001).
Conclusions
Larger VVV in SBP was significantly associated with an increased plaque burden and lipid composition at the culprit lesion of a coronary artery in CAD patients. The improvement of VVV in SBP may contribute to the regression and stabilization of coronary plaques.
Figure 1
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- Y Kato
- Fukuoka University School of Medicine, Fukuoka, Japan
| | - A Iwata
- Fukuoka University School of Medicine, Fukuoka, Japan
| | - S Miura
- Fukuoka University School of Medicine, Fukuoka, Japan
| |
Collapse
|
21
|
Fukunaga M, Masuda H, Isotani A, Morinaga T, Yano M, Miura S, Ando K. Different clinical features between left atrial and left atrial appendage thrombus: an insight into more than 16,000 transesophageal echography database. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2388] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Thrombosis localization inside the left atrium (LA) is very frequently in the left atrial appendage (LAA). Some cases show atrial thrombus outside LAA, whose characteristics have not well elucidated.
Purpose
To reveal the different clinical background between thrombus inside LAA and outside LAA in a large transesophageal echo (TEE) database.
Methods
We searched the TEE database over 8 years of our center to identify patients in whom LA thrombus was pointed out. After initial TEE imaging, LA thrombus was confirmed with repeated TEE by echocardiography specialist or other modality, such as CT images.
Results
In a consecutive 16,142 TEE cases, LA thrombus was suspected in 162 cases (1%), finally 38 cases were identified as LA thrombus. They were divided into two groups; LAA only group and outside LAA group. Atrial fibrillation was concomitant in 34 patients (89%). History of stroke was significantly higher in LAA group (46.2% vs 8.3%, p=0.03) and malignant tumor was significantly higher in outside LAA group (23.1% vs 58.3%, p=0.035). LA thrombus was the first symptom in 3 cases of outside LAA group, following by malignant tumor was newly detected. Oral anticoagulation was prescribed in 23 cases (61%) at TEE study, mostly treated with warfarin, and median 123 days later thrombus dissolution was confirmed in 21 cases (55%). During mean follow up of 893 days, 4 patients experienced ischemic stroke, but two of them were due to self-interruption.
Conclusion
Outside LAA thrombus is minor but more concomitant with malignant tumor. Physician must be aware that screening of cancer is important if outside LAA thrombus is detected.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- M Fukunaga
- Kokura Memorial Hospital, Kitakyushu, Japan
| | - H Masuda
- Kokura Memorial Hospital, Kitakyushu, Japan
| | - A Isotani
- Kokura Memorial Hospital, Kitakyushu, Japan
| | - T Morinaga
- Kokura Memorial Hospital, Kitakyushu, Japan
| | - M Yano
- Kokura Memorial Hospital, Kitakyushu, Japan
| | - S Miura
- Kokura Memorial Hospital, Kitakyushu, Japan
| | - K Ando
- Kokura Memorial Hospital, Kitakyushu, Japan
| |
Collapse
|
22
|
Yang JH, Schuler M, Popat S, Miura S, Heeke S, Passaro A, de Marinis F, Park K, Kim E. 1341P Afatinib in Asian and non-Asian patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC harboring uncommon mutations. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1655] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
23
|
Miura S, Kubota K, Yamabe K. PDB4 Study on Standard Criteria of SERUM Uric Acid and Factors of High Uric Acid in Children Using Claims Database in JAPAN. Value Health Reg Issues 2020. [DOI: 10.1016/j.vhri.2020.07.163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
24
|
Matsuda R, Tamamoto T, Sugimoto T, Hontsu S, Yamaki K, Miura S, Takeshima Y, Tamura K, Yamada S, Nishimura F, Nakagawa I, Motoyama Y, Park YS, Nakase H, Hasegawa M. Linac-based fractionated stereotactic radiotherapy with a micro-multileaf collimator for large brain metastasis unsuitable for surgical resection. J Radiat Res 2020; 61:546-553. [PMID: 32548618 PMCID: PMC7336818 DOI: 10.1093/jrr/rraa038] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/10/2020] [Revised: 04/27/2020] [Indexed: 05/21/2023]
Abstract
The aim of this study was to assess clinical outcomes using linac-based, fractionated, stereotactic radiotherapy (fSRT) with a micro-multileaf collimator for large brain metastasis (LBM) unsuitable for surgical resection. Between January 2009 and October 2018 we treated 21 patients with LBM using linac-based fSRT. LBM was defined as a tumor with ≥30 mm maximal diameter in gadolinium-enhanced magnetic resonance images. LBMs originated from the lung (n = 17, 81%), ovary (n = 2, 9.5%), rectum (n = 1, 4.8%) and esophagus (n = 1, 4.8%). The median pretreatment Karnofsky performance status was 50 (range: 50-80). Recursive partition analysis (RPA) was as follows: Classes 2 and 3 were 7 and 14 patients, respectively. The median follow-up was 5 months (range: 1-86 months). The range of tumor volume was 8.7-26.5 cm3 (median: 17.1 cm3). All patients were basically treated with 35Gy in 5 fractions, except in three cases. The progression-free survival was 3.0 months. The median survival time was 7.0 months. There was no permanent radiation injury in any of the patients. Radiation-caused central nervous system necrosis, according to the Common Terminology Criteria for Adverse Events version 4.0, occurred in one patient (grade 3). One patients received bevacizumab for radiation necrosis. Two patients underwent additional surgical resection due to local progression and cyst formation. For patients with LBM unsuitable for surgical resection, linac-based fSRT is a promising therapeutic alternative.
Collapse
Affiliation(s)
- Ryosuke Matsuda
- Department of Neurosurgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan
| | - Tetsuro Tamamoto
- Department of Radiation Oncology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan
- Corresponding author. Department of Radiation Oncology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan. Tel: +81-744-22-3051; Fax: +81-744-29-0818;
| | - Tadashi Sugimoto
- Department of Neurosurgery, Osaka General Medical Center, 3-1-56 Mandaihigashi, Sumiyoshi-ku, Osaka, Osaka 558-8558, Japan
| | - Shigeto Hontsu
- Department of Respiratory medicine, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan
| | - Kaori Yamaki
- Department of Radiation Oncology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan
| | - Sachiko Miura
- Department of Radiation Oncology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan
| | - Yasuhiro Takeshima
- Department of Neurosurgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan
| | - Kentaro Tamura
- Department of Neurosurgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan
| | - Shuichi Yamada
- Department of Neurosurgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan
| | - Fumihiko Nishimura
- Department of Neurosurgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan
| | - Ichiro Nakagawa
- Department of Neurosurgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan
| | - Yasushi Motoyama
- Department of Neurosurgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan
| | - Young-Su Park
- Department of Neurosurgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan
| | - Hiroyuki Nakase
- Department of Neurosurgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan
| | - Masatoshi Hasegawa
- Department of Radiation Oncology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan
| |
Collapse
|
25
|
Hino Y, Yamada Y, Miura S, Okada F, Uchiyama T, Mabuchi S. Clitoral metastasis from uterine cervical cancer: A case report and review of the literature. Gynecol Oncol Rep 2020; 33:100591. [PMID: 32637526 PMCID: PMC7327413 DOI: 10.1016/j.gore.2020.100591] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/01/2020] [Revised: 04/27/2020] [Accepted: 05/03/2020] [Indexed: 11/19/2022] Open
Abstract
We describe a rare case with a clitoral metastasis from uterine cervical cancer. The patient was treated by concurrent chemoradiotherapy and clitoridectomy. Clitoral metastasis should be considered in patients with clitorodynia.
A 81-year-old woman vaginal bleeding and vulvar pain. Pretreatment work-up revealed a 4.5 cm cervical cancer extended to the lower-third of the vagina and an isolated clitoral metastasis. The patient was treated with a multimodal treatment consisting with radiotherapy followed by clitoridectomy. She recovered uneventfully following the multimodal treatment, and is currently free of disease. Clitoral metastasis is extremely rare, however, this condition should be considered in cervical cancer patients during the pretreatment work-up or follow-up period, especially when patients complain of clitoral pain or enlargement.
Collapse
Affiliation(s)
- Yukiko Hino
- Department of Obstetrics and Gynecology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan
| | - Yuki Yamada
- Department of Obstetrics and Gynecology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan
| | - Sachiko Miura
- Department of Department of Radiation Oncology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan
| | - Fumi Okada
- Department of Diagnostic Pathology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan
| | - Tomoko Uchiyama
- Department of Diagnostic Pathology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan
| | - Seiji Mabuchi
- Department of Obstetrics and Gynecology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan
| |
Collapse
|
26
|
Nishida T, Yamaguchi M, Miura S, Waga K, Kawabata N, Syaifudin M, Kashiwakura I. Radiomitigative Effects of Approved Hematopoietic Drugs on Mice Exposed to Lethal Total-body Irradiation. Atom Indo 2020. [DOI: 10.17146/aij.2020.950] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
|
27
|
Miura S, Fukushima M, Kurosawa H, Kimura S. Epidemiology of long-stay patients in the pediatric intensive care unit: prevalence, characteristics, resource consumption and complications. Z Gesundh Wiss 2020; 30:111-119. [PMID: 32421088 PMCID: PMC7223791 DOI: 10.1007/s10389-020-01282-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/02/2019] [Accepted: 04/01/2020] [Indexed: 11/03/2022]
Abstract
Background The impact of pediatric intensive care unit (PICU) utilization and resource consumption among long-stay patients has not been characterized recently. This study aimed to describe the resource consumption and characteristics of long-stay patients in a PICU. Methods This was a single-center descriptive cohort study of 1309 patients admitted to a PICU in 2017. The main outcome was ICU length of stay (LOS). Patients were divided into prolonged LOS (PLS) and non-PLS groups if they had an LOS of ≥ 28 or < 28 days, respectively. Two groups were compared to characterize PLS. Results Thirty-two (2.4%) patients had a PLS and utilized 33% of PICU bed days. Factors associated with PLS with odds ratio [95% confidence interval (CI)] were being a neonate (7.8 [2.5-25.4], p = <0.001), being an infant (2.9 [1.0-9.0], p = 0.04), admission for a respiratory ailment (7.3 [1.6-44.2], p = 0.003), cardiovascular dysfunction (24.1 [4.8-152.1], p = <0.001), post-cardiac operation (8.0 [1.7-50.1], p = 0.003), post-cardiopulmonary arrest (22.8 [1.7-211.9], p = 0.01), and transfer from another facility (4.2 [1.8-10.7], p = 0.001). PLS patients developed more nosocomial infections and disproportionately received monitoring and therapeutic resources. Conclusions A PLS was associated with substantial PICU utilization and complication rates. Future studies should aim to alleviate both institutional and patient-related issues in the affected population harboring possible risk factors for PLS.
Collapse
Affiliation(s)
- S Miura
- Department of Pediatric Intensive Care, Saitama Children's Medical Center, 1-2, Shintoshin, Saitama, Chuou-ku 330-8777 Japan
| | - M Fukushima
- Department of Pediatric Intensive Care, Saitama Children's Medical Center, 1-2, Shintoshin, Saitama, Chuou-ku 330-8777 Japan
| | - H Kurosawa
- Department of Pediatric Intensive Care, Saitama Children's Medical Center, 1-2, Shintoshin, Saitama, Chuou-ku 330-8777 Japan
| | - S Kimura
- Department of Pediatric Intensive Care, Saitama Children's Medical Center, 1-2, Shintoshin, Saitama, Chuou-ku 330-8777 Japan
| |
Collapse
|
28
|
Matsuda KM, Koguchi A, Toyama T, Sakuishi K, Kobayashi M, Miura S, Miyazaki M, Suga H, Asano Y, Toda T, Sato S. Concurrence of polyarteritis nodosa and multiple sclerosis. J Eur Acad Dermatol Venereol 2019; 34:e188-e191. [PMID: 31769115 DOI: 10.1111/jdv.16107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- K M Matsuda
- Department of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan
| | - A Koguchi
- Department of Neurology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan
| | - T Toyama
- Department of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan
| | - K Sakuishi
- Department of Neurology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan
| | - M Kobayashi
- Department of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan
| | - S Miura
- Department of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan
| | - M Miyazaki
- Department of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan
| | - H Suga
- Department of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan
| | - Y Asano
- Department of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan
| | - T Toda
- Department of Neurology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan
| | - S Sato
- Department of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan
| |
Collapse
|
29
|
Tanaka K, Morita S, Ando M, Yokoyama T, Nakamura A, Yoshioka H, Ishiguro T, Miura S, Toyozawa R, Oguri T, Daga H, Ko R, Bessho A, Tachihara M, Iwamoto Y, Hirano K, Nakanishi Y, Nakagawa K, Yamamoto N, Okamoto I. MA13.06 Ph3 Study of Maintenance Therapy with S-1 vs BSC After Induction Therapy with Carboplatin + S-1 for Advanced Squamous Cell Lung Cancer (WJOG7512L). J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.605] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
30
|
Otani S, Yamada K, Miyamoto S, Azuma K, Ishii H, Bessho A, Hosokawa S, Kunitoh H, Miyazaki K, Tanaka H, Miura S, Aono H, Nakahara Y, Kusaka K, Hosomi Y, Hamada A, Okamoto H. MA21.11 A Multicenter Phase II Study of Low-Dose Erlotinib in Frail Patients with EGFR Mutation-Positive, Non-Small Cell Lung Cancer: TORG1425. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.681] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
31
|
Watanabe S, Matsumoto N, Koshio J, Ishida A, Tanaka T, Abe T, Ishikawa D, Shoji S, Nozaki K, Ichikawa K, Kondo R, Otsubo A, Aoki A, Kajiwara T, Koyama K, Miura S, Yoshizawa H, Kikuchi T. MA21.05 Phase II Trial of the Combination of Alectinib with Bevacizumab in ALK-Positive Nonsquamous Non-Small Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.676] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
32
|
Kuzumi A, Yoshizaki A, Fukasawa T, Ebata S, Miura S, Yoshizaki A, Sumida H, Asano Y, Sato S. Serum levels of human β-defensin 2: possible association with fibrosis and vasculopathy in patients with systemic sclerosis. J Eur Acad Dermatol Venereol 2019; 33:e272-e274. [PMID: 30835873 DOI: 10.1111/jdv.15546] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Affiliation(s)
- A Kuzumi
- Department of Dermatology, University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
| | - A Yoshizaki
- Department of Dermatology, University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
| | - T Fukasawa
- Department of Dermatology, University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
| | - S Ebata
- Department of Dermatology, University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
| | - S Miura
- Department of Dermatology, University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
| | - A Yoshizaki
- Department of Dermatology, University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
| | - H Sumida
- Department of Dermatology, University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
| | - Y Asano
- Department of Dermatology, University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
| | - S Sato
- Department of Dermatology, University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
| |
Collapse
|
33
|
Etoh S, Kawamura K, Tomonaga K, Miura S, Harada S, Kikuno S, Ueno M, Miyata R, Shimodozono M. The effects of neuromuscular electrical stimulation during repetitive transcranial magnetic stimulation before repetitive facilitation exercise on the hemiparetic hand in chronic stroke patients. Brain Stimul 2019. [DOI: 10.1016/j.brs.2018.12.343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
34
|
Masuda H, Miura S, Harano K, Wang Y, Hirota Y, Matsunaga Y, Lim B, Lucci A, Parinyanitikul N, Lee HJ, Gong G, Rao A, Seitz RS, Morris SW, Hout DR, Nakamura S, Tripathy D, Harada O, Krishnamurthy S, Ueno NT. Abstract P4-02-05: Apocrine morphology and LAR molecular subtype predict prognosis of TNBC patients with residual disease after neoadjuvant chemotherapy. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-02-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: TNBC molecular subtype classification updated by Lehmann et al. includes 4 subtypes: basal-like 1 and 2 (BL1), (BL2), mesenchymal (M), and luminal androgen receptor (LAR), and as a modifier of these subtypes, an Immunomodulatory (IM) gene expression signature. However, molecular subtypes have not been linked to morphological features of TNBC. Apocrine carcinoma has been proposed as a TNBC category that expresses androgen receptor. LAR-subtype TNBC has a poor response to neoadjuvant systemic therapy (NST). We hypothesized that defining the apocrine-featured TNBC by morphology and molecular subtype predict the prognosis of patients with residual disease after NST. Methods: We created the Pan-Pacific TNBC Consortium dataset, which contains paired samples of matched pre and post-NST TNBC tumors from 4 institutions. All patients received NST and didn't have a pathological complete response (pCR). Three pathologists examined hematoxylin and eosin-stained slides of 86 pre-NST samples and determined (1) the presence of apocrine differentiation, (2) the level of tumor-infiltrating lymphocytes (TILs), (3) the histological grade (HG), and (4) the rate of necrosis. These morphological features were compared among the subtypes. For a sample to be considered apocrine positive, apocrine differentiation had to be identified by 2 or more pathologists. Fisher's exact test was used to test the association of subtypes and morphological features. The log-rank test was used to compare disease-free survival (DFS). Results: Twelve of 24 (50%) apocrine-positive tumor samples were LAR subtype, and12 of 17 (70%) LAR-subtype tumor samples exhibited apocrine differentiation. The other subtypes showed following: BL1, 11/44 (25%); BL2, 0/7 (0%); M, 1/10 (10%); unclassified, 0/8 (0%). The median follow-up time was 22 months. In all populations, 2-year DFS rates were higher in patients with apocrine-positive tumors than in those whose tumors did not exhibit apocrine differentiation (P = .027; 2-year DFS, 85% vs 54%). The LAR subtype was also associated with lower HG, although LAR tumors had a similar prognosis to the other subtypes. In the combined analysis of subtypes and apocrine differentiation, patients with apocrine-positive LAR tumors had a higher 2-year DFS rate than did those with apocrine-negative LAR tumors (P = .044; 2-year DFS, 88% vs. 30%). However, patients with apocrine-positive BL1 tumors had no better DFS than did those with apocrine-negative BL1 tumors (P = .133). TIL levels and the presence of the IM signature were positively associated (P = .01), and apocrine differentiation positivity tended to be negatively associated with TIL level (P = .06). Neither TIL level nor IM signature was associated with survival. Conclusion: Apocrine differentiation was associated with the LAR subtype of TNBC and better prognosis in patients who did not have a pCR. The LAR subtype alone did not predict DFS; however, LAR tumors with apocrine differentiation had a better prognosis than did LAR tumors without apocrine differentiation. Using a combination of morphologic and genomic testing may be helpful in determining the prognosis of patients with apocrine-positive TNBC tumors who have residual disease after NST.
Citation Format: Masuda H, Miura S, Harano K, Wang Y, Hirota Y, Matsunaga Y, Lim B, Lucci A, Parinyanitikul N, Lee HJ, Gong G, Rao A, Seitz RS, Morris SW, Hout DR, Nakamura S, Tripathy D, Harada O, Krishnamurthy S, Ueno NT. Apocrine morphology and LAR molecular subtype predict prognosis of TNBC patients with residual disease after neoadjuvant chemotherapy [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-02-05.
Collapse
Affiliation(s)
- H Masuda
- Showa University, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan; The University of Texas MD Anderson Cancer Center, Houston; Chulalongkorn University, Bangkok, Thailand; University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea; Insight Genetics, Inc.,, Nashville, TN; Kameda General Hospital, Kamogawa, Japan
| | - S Miura
- Showa University, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan; The University of Texas MD Anderson Cancer Center, Houston; Chulalongkorn University, Bangkok, Thailand; University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea; Insight Genetics, Inc.,, Nashville, TN; Kameda General Hospital, Kamogawa, Japan
| | - K Harano
- Showa University, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan; The University of Texas MD Anderson Cancer Center, Houston; Chulalongkorn University, Bangkok, Thailand; University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea; Insight Genetics, Inc.,, Nashville, TN; Kameda General Hospital, Kamogawa, Japan
| | - Y Wang
- Showa University, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan; The University of Texas MD Anderson Cancer Center, Houston; Chulalongkorn University, Bangkok, Thailand; University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea; Insight Genetics, Inc.,, Nashville, TN; Kameda General Hospital, Kamogawa, Japan
| | - Y Hirota
- Showa University, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan; The University of Texas MD Anderson Cancer Center, Houston; Chulalongkorn University, Bangkok, Thailand; University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea; Insight Genetics, Inc.,, Nashville, TN; Kameda General Hospital, Kamogawa, Japan
| | - Y Matsunaga
- Showa University, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan; The University of Texas MD Anderson Cancer Center, Houston; Chulalongkorn University, Bangkok, Thailand; University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea; Insight Genetics, Inc.,, Nashville, TN; Kameda General Hospital, Kamogawa, Japan
| | - B Lim
- Showa University, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan; The University of Texas MD Anderson Cancer Center, Houston; Chulalongkorn University, Bangkok, Thailand; University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea; Insight Genetics, Inc.,, Nashville, TN; Kameda General Hospital, Kamogawa, Japan
| | - A Lucci
- Showa University, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan; The University of Texas MD Anderson Cancer Center, Houston; Chulalongkorn University, Bangkok, Thailand; University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea; Insight Genetics, Inc.,, Nashville, TN; Kameda General Hospital, Kamogawa, Japan
| | - N Parinyanitikul
- Showa University, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan; The University of Texas MD Anderson Cancer Center, Houston; Chulalongkorn University, Bangkok, Thailand; University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea; Insight Genetics, Inc.,, Nashville, TN; Kameda General Hospital, Kamogawa, Japan
| | - HJ Lee
- Showa University, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan; The University of Texas MD Anderson Cancer Center, Houston; Chulalongkorn University, Bangkok, Thailand; University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea; Insight Genetics, Inc.,, Nashville, TN; Kameda General Hospital, Kamogawa, Japan
| | - G Gong
- Showa University, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan; The University of Texas MD Anderson Cancer Center, Houston; Chulalongkorn University, Bangkok, Thailand; University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea; Insight Genetics, Inc.,, Nashville, TN; Kameda General Hospital, Kamogawa, Japan
| | - A Rao
- Showa University, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan; The University of Texas MD Anderson Cancer Center, Houston; Chulalongkorn University, Bangkok, Thailand; University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea; Insight Genetics, Inc.,, Nashville, TN; Kameda General Hospital, Kamogawa, Japan
| | - RS Seitz
- Showa University, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan; The University of Texas MD Anderson Cancer Center, Houston; Chulalongkorn University, Bangkok, Thailand; University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea; Insight Genetics, Inc.,, Nashville, TN; Kameda General Hospital, Kamogawa, Japan
| | - SW Morris
- Showa University, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan; The University of Texas MD Anderson Cancer Center, Houston; Chulalongkorn University, Bangkok, Thailand; University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea; Insight Genetics, Inc.,, Nashville, TN; Kameda General Hospital, Kamogawa, Japan
| | - DR Hout
- Showa University, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan; The University of Texas MD Anderson Cancer Center, Houston; Chulalongkorn University, Bangkok, Thailand; University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea; Insight Genetics, Inc.,, Nashville, TN; Kameda General Hospital, Kamogawa, Japan
| | - S Nakamura
- Showa University, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan; The University of Texas MD Anderson Cancer Center, Houston; Chulalongkorn University, Bangkok, Thailand; University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea; Insight Genetics, Inc.,, Nashville, TN; Kameda General Hospital, Kamogawa, Japan
| | - D Tripathy
- Showa University, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan; The University of Texas MD Anderson Cancer Center, Houston; Chulalongkorn University, Bangkok, Thailand; University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea; Insight Genetics, Inc.,, Nashville, TN; Kameda General Hospital, Kamogawa, Japan
| | - O Harada
- Showa University, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan; The University of Texas MD Anderson Cancer Center, Houston; Chulalongkorn University, Bangkok, Thailand; University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea; Insight Genetics, Inc.,, Nashville, TN; Kameda General Hospital, Kamogawa, Japan
| | - S Krishnamurthy
- Showa University, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan; The University of Texas MD Anderson Cancer Center, Houston; Chulalongkorn University, Bangkok, Thailand; University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea; Insight Genetics, Inc.,, Nashville, TN; Kameda General Hospital, Kamogawa, Japan
| | - NT Ueno
- Showa University, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan; The University of Texas MD Anderson Cancer Center, Houston; Chulalongkorn University, Bangkok, Thailand; University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea; Insight Genetics, Inc.,, Nashville, TN; Kameda General Hospital, Kamogawa, Japan
| |
Collapse
|
35
|
Miyagawa T, Asano Y, Saigusa R, Hirabayashi M, Yamashita T, Taniguchi T, Takahashi T, Nakamura K, Miura S, Yoshizaki A, Miyagaki T, Sato S. A potential contribution of trappin‐2 to the development of vasculopathy in systemic sclerosis. J Eur Acad Dermatol Venereol 2019; 33:753-760. [DOI: 10.1111/jdv.15387] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2018] [Accepted: 10/29/2018] [Indexed: 11/30/2022]
Affiliation(s)
- T. Miyagawa
- Department of Dermatology University of Tokyo Graduate School of Medicine Tokyo Japan
| | - Y. Asano
- Department of Dermatology University of Tokyo Graduate School of Medicine Tokyo Japan
| | - R. Saigusa
- Department of Dermatology University of Tokyo Graduate School of Medicine Tokyo Japan
| | - M. Hirabayashi
- Department of Dermatology University of Tokyo Graduate School of Medicine Tokyo Japan
| | - T. Yamashita
- Department of Dermatology University of Tokyo Graduate School of Medicine Tokyo Japan
| | - T. Taniguchi
- Department of Dermatology University of Tokyo Graduate School of Medicine Tokyo Japan
| | - T. Takahashi
- Department of Dermatology University of Tokyo Graduate School of Medicine Tokyo Japan
| | - K. Nakamura
- Department of Dermatology University of Tokyo Graduate School of Medicine Tokyo Japan
| | - S. Miura
- Department of Dermatology University of Tokyo Graduate School of Medicine Tokyo Japan
| | - A. Yoshizaki
- Department of Dermatology University of Tokyo Graduate School of Medicine Tokyo Japan
| | - T. Miyagaki
- Department of Dermatology University of Tokyo Graduate School of Medicine Tokyo Japan
| | - S. Sato
- Department of Dermatology University of Tokyo Graduate School of Medicine Tokyo Japan
| |
Collapse
|
36
|
K. M, Higashijima ,A, Hasegawa Y, Miura S, Yoshiura KI, Masuzaki H. Decreased cell-free but not exosomal miR-518b in maternal plasma is caused by amniocentesis. CLIN EXP OBSTET GYN 2018. [DOI: 10.12891/ceog4351.2018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
|
37
|
Miura K, Higashijima A, Hasegawa Y, Miura S, Yoshida A, Masuzaki H. Decreased plasma concentrations of pregnancy-associated placenta-specific microRNAs in pregnancies with a diagnosis of fetal trisomy 18. CLIN EXP OBSTET GYN 2018. [DOI: 10.12891/ceog4355.2018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
|
38
|
Kawaguchi T, Sawabata N, Miura S, Kawai N, Yasukawa M, Tojo T, Taniguchi S. Prognostic impact of underlying lung disease in pulmonary wedge resection for lung cancer. Int J Clin Oncol 2018; 24:366-374. [PMID: 30443810 DOI: 10.1007/s10147-018-1367-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2018] [Accepted: 11/01/2018] [Indexed: 12/25/2022]
Abstract
BACKGROUND Pulmonary wedge resection is an option for lung cancer patients with limited cardiopulmonary preservation. As the impact of underlying lung status on the prognosis of such patients remains unclear, we assessed this issue. METHODS A total of 149 borderline surgical candidates with localized lung cancer who had undergone wedge resection were retrospectively investigated. Clinical variables related to perioperative morbidity, local control rate, and oncological outcomes based on underlying lung disease were analyzed. RESULTS According to the risk analysis of postoperative complications, underlying lung disease did not influence the surgical morbidity. Postoperative recurrence occurred in 65 patients (locoregional recurrence in 36, distant metastasis in 12, and both simultaneously in 17). Multivariate analysis revealed that emphysema on computed tomography (CT) [hazard ratio (HR) 0.45; 95% confidence interval (CI) 0.21-0.99] was an independent indicator of locoregional recurrence. Forty-four patients died of lung cancer and 29 of other causes. Multivariate analysis demonstrated that interstitial lung disease on CT (HR 1.98; 95% CI 1.01-3.89) was a predictor of poor prognosis. CONCLUSION Pulmonary wedge resection can be safely undergone by lung cancer patients regardless of pulmonary comorbidity, although underlying lung disease may influence the prognosis after wedge resection.
Collapse
Affiliation(s)
- Takeshi Kawaguchi
- Department of Thoracic and Cardiovascular Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan.
| | - Noriyoshi Sawabata
- Department of Thoracic and Cardiovascular Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan
| | - Sachiko Miura
- Department of Radiation Oncology, Nara Medical University, Kashihara, Nara, Japan
| | - Norikazu Kawai
- Department of Thoracic and Cardiovascular Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan
| | - Motoaki Yasukawa
- Department of Thoracic and Cardiovascular Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan
| | - Takashi Tojo
- Department of Thoracic and Cardiovascular Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan
| | - Shigeki Taniguchi
- Department of Thoracic and Cardiovascular Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan
| |
Collapse
|
39
|
Kawaguchi T, Sawabata N, Nakai T, Miura S, Kawai N, Yasukawa M, Tojo T, Ohbayashi C, Taniguchi S. Clinical and pathological characteristics of surgically resected intrapulmonary lymph nodes: Can they be differentiated from other malignant nodules? Respir Investig 2018; 56:473-479. [PMID: 30361051 DOI: 10.1016/j.resinv.2018.08.002] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2018] [Revised: 07/07/2018] [Accepted: 08/02/2018] [Indexed: 11/28/2022]
Abstract
BACKGROUND Intrapulmonary lymph nodes (IPLNs) are often recognized as sub-centimeter solid pulmonary nodules (SCPNs). The present study investigated their clinical and pathological characteristics to allow clinicians to distinguish them from malignant nodules. METHODS Among 194 SCPNs surgically resected between 2006 and 2016, 26 IPLNs were investigated histopathologically. In addition, 145 resected malignant SCPNs were compared radiographically with the 26 IPLNs. RESULTS Radiographically, most IPLNs were in a middle or lower lobe, and all lesions were within 20 mm of the visceral pleura. Enlargement was seen in one lesion. Three lesions demonstrated linear density contiguous to pleura (LD), and 13 lesions were adjacent to the peripheral pulmonary vein (APV). Microscopically, all IPLNs showed adjacency to pulmonary veins, 23 showed interlobular septa extending from the IPLN, and 18 were surrounded by a dilatated lymphoid channel. Radiographical findings of LD and APV were also seen in malignant SCPNs (LD, 12/145; APV, 25/145). Comparative analysis revealed that enlargement and APV were significant predictors differentiating IPLNs from malignant SCPNs. The sensitivity/specificity of enlargement and APV were 92%/92% and 17%/50%, respectively. CONCLUSIONS IPLNs show typical high-resolution computed tomography findings that reflect their histopathological characteristics. Such findings help identify IPLNs prior to surgery. Specifically, enlargement and APV may differentiate IPLNs from malignant SCPNs. However, atypical cases are also possible, and radiological findings are not specific for differentiating IPLNs from malignant lesions. Thus, clinicians should consider surgical exploration when diagnosing SCPNs.
Collapse
Affiliation(s)
- Takeshi Kawaguchi
- Department of Thoracic and Cardiovascular Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
| | - Noriyoshi Sawabata
- Department of Thoracic and Cardiovascular Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan
| | - Tokiko Nakai
- Department of Diagnostic Pathology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan
| | - Sachiko Miura
- Department of Radiation Oncology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan
| | - Norikazu Kawai
- Department of Thoracic and Cardiovascular Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan
| | - Motoaki Yasukawa
- Department of Thoracic and Cardiovascular Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan
| | - Takashi Tojo
- Department of Thoracic and Cardiovascular Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan
| | - Chiho Ohbayashi
- Department of Diagnostic Pathology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan
| | - Shigeki Taniguchi
- Department of Thoracic and Cardiovascular Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan
| |
Collapse
|
40
|
Ishida N, Ike A, Matsuoka Y, Sugihara M, Nishikawa H, Saku K, Miura S. Lipid profiles associated with maces among hemodialysis patients with percutaneous coronary intervention: From the fu-registry. Atherosclerosis 2018. [DOI: 10.1016/j.atherosclerosis.2018.06.597] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
41
|
Okuno T, Koseki K, Nakanishi T, Ninomiya K, Tanaka T, Sato Y, Osanai A, Sato K, Koike H, Yahagi K, Komiyama K, Aoki J, Yokozuka M, Miura S, Tanabe K. P1669Prognostic impact of computed tomography-derived abdominal fat area in patients undergoing transcatheter aortic valve implantation. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p1669] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- T Okuno
- Mitsui Memorial Hospital, Division of Cardiology, Tokyo, Japan
| | - K Koseki
- Mitsui Memorial Hospital, Division of Cardiology, Tokyo, Japan
| | - T Nakanishi
- Mitsui Memorial Hospital, Division of Cardiology, Tokyo, Japan
| | - K Ninomiya
- Mitsui Memorial Hospital, Division of Cardiology, Tokyo, Japan
| | - T Tanaka
- Mitsui Memorial Hospital, Division of Cardiology, Tokyo, Japan
| | - Y Sato
- Mitsui Memorial Hospital, Division of Cardiology, Tokyo, Japan
| | - A Osanai
- Mitsui Memorial Hospital, Division of Cardiovascular Surgery, Tokyo, Japan
| | - K Sato
- Mitsui Memorial Hospital, Division of Cardiology, Tokyo, Japan
| | - H Koike
- Mitsui Memorial Hospital, Division of Cardiology, Tokyo, Japan
| | - K Yahagi
- Mitsui Memorial Hospital, Division of Cardiology, Tokyo, Japan
| | - K Komiyama
- Mitsui Memorial Hospital, Division of Cardiology, Tokyo, Japan
| | - J Aoki
- Mitsui Memorial Hospital, Division of Cardiology, Tokyo, Japan
| | - M Yokozuka
- Mitsui Memorial Hospital, Division of Anesthesia, Tokyo, Japan
| | - S Miura
- Mitsui Memorial Hospital, Division of Cardiovascular Surgery, Tokyo, Japan
| | - K Tanabe
- Mitsui Memorial Hospital, Division of Cardiology, Tokyo, Japan
| |
Collapse
|
42
|
Okuno T, Koseki K, Nakanishi T, Ninomiya K, Tanaka T, Sato Y, Osanai A, Sato K, Koike H, Yahagi K, Komiyama K, Aoki J, Yokozuka M, Miura S, Tanabe K. P1673Impact of objective nutritional indexes on one-year clinical outcomes after transcatheter aortic valve implanation. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p1673] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- T Okuno
- Mitsui Memorial Hospital, Division of Cardiology, Tokyo, Japan
| | - K Koseki
- Mitsui Memorial Hospital, Division of Cardiology, Tokyo, Japan
| | - T Nakanishi
- Mitsui Memorial Hospital, Division of Cardiology, Tokyo, Japan
| | - K Ninomiya
- Mitsui Memorial Hospital, Division of Cardiology, Tokyo, Japan
| | - T Tanaka
- Mitsui Memorial Hospital, Division of Cardiology, Tokyo, Japan
| | - Y Sato
- Mitsui Memorial Hospital, Division of Cardiology, Tokyo, Japan
| | - A Osanai
- Mitsui Memorial Hospital, Division of Cardiovascular Surgery, Tokyo, Japan
| | - K Sato
- Mitsui Memorial Hospital, Division of Cardiology, Tokyo, Japan
| | - H Koike
- Mitsui Memorial Hospital, Division of Cardiology, Tokyo, Japan
| | - K Yahagi
- Mitsui Memorial Hospital, Division of Cardiology, Tokyo, Japan
| | - K Komiyama
- Mitsui Memorial Hospital, Division of Cardiology, Tokyo, Japan
| | - J Aoki
- Mitsui Memorial Hospital, Division of Cardiology, Tokyo, Japan
| | - M Yokozuka
- Mitsui Memorial Hospital, Division of Anesthesia, Tokyo, Japan
| | - S Miura
- Mitsui Memorial Hospital, Division of Cardiovascular Surgery, Tokyo, Japan
| | - K Tanabe
- Mitsui Memorial Hospital, Division of Cardiology, Tokyo, Japan
| |
Collapse
|
43
|
Ike A, Matsuoka Y, Ishida N, Sugihara M, Nishikawa H, Shirai K, Miura S, Saku K. Sex difference between target levels of cholesterol-related parameters and post-PCI long-term clinical outcomes: From the FU-Registry. Atherosclerosis 2018. [DOI: 10.1016/j.atherosclerosis.2018.06.703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
44
|
Fujimura Y, Ikeda Y, Miura S, Yoshida E, Shima H, Nishida S, Suzuki M, Titani K, Taniuchi Y, Kawasaki T. Isolation and Characterization of jararaca GPIb-BP, a Snake Venom Antagonist Specific to Platelet Glycoprotein lb. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1649807] [Citation(s) in RCA: 45] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryA platelet glycoprotein lb-binding protein (GPIb-BP) was isolated from the snake venom of Bothrops jararaca. Jararaca GPIb-BP showed a single band with Mr of 30,000, and two distinct bands with Mr. of 17,000/13,000 under non-reducing and reducing conditions, respectively, on SDS-polyacrylamide gel electrophoresis. Jararaca GPIb-BP itself induced neither platelet aggregation nor serotonin release from platelets, but specifically bound to GPIb (40,629 ± 2,521 molecules per normal platelet, with Kd 39.1 ± 2.4 nM at saturation). The purified venom protein completely inhibited ristocetin- or botrocetin-induccd von Willebrand factor (vWF) binding, and blocked the bovine vWF binding to GPIb, with IC50 values ranging from 28 to 42 nM, without affecting the platelet aggregation induced by ADP or α-thrombin. 1251-jararaca GPIb-BP binding to GPIb was not altered by the presence of human α-thrombin. Jararaca GPIb-BP at a final concentration of 104 nM totally abolished vWF-dependent shear- induced platelet aggregation (SIPA) at a high shear stress, but had no effect on SIPA at a low shear stress. Reduced and S-carboxyamidomethylated jararaca GPIb-BP lost its inhibitory activity on SIPA. The NH2-terminal amino acid sequences of the subunits revealed a high degree of homology with those of several Ca2+-dependent lectins, especially to those of two functionally opposite venom proteins, botrocetin (a vWF-modulator) and alboaggregin-B (a GPIb- modulator).
Collapse
Affiliation(s)
- Y Fujimura
- The Department of Blood Transfusion, Nara Medical University, Kashlhara, Nara, Japan
| | - Y Ikeda
- The Department of Internal Medicine, Keio University School of Medicine, Shinjuku, Tokyo, Japan
| | - S Miura
- The Department of Blood Transfusion, Nara Medical University, Kashlhara, Nara, Japan
| | - E Yoshida
- The Department of Blood Transfusion, Nara Medical University, Kashlhara, Nara, Japan
| | - H Shima
- The Department of Blood Transfusion, Nara Medical University, Kashlhara, Nara, Japan
| | - S Nishida
- The Department of Blood Transfusion, Nara Medical University, Kashlhara, Nara, Japan
| | - M Suzuki
- The Institute for Comprehensive Medical Science, Fujita Health University, Toyoake, Aichi, Japan
| | - K Titani
- The Institute for Comprehensive Medical Science, Fujita Health University, Toyoake, Aichi, Japan
| | - Y Taniuchi
- The Research Institute of Yamanouchi Pharmaceutical Co., Ibaraki, Japan
| | - T Kawasaki
- The Research Institute of Yamanouchi Pharmaceutical Co., Ibaraki, Japan
| |
Collapse
|
45
|
Fujimura Y, Miyata S, Nishida S, Miura S, Kaneda M, Yoshioka A, Fukui H, Katayama M, Tuddenham EGD, Usami Y, Titani K. The Interaction of Botrocetin with Normal or Variant von Willebrand Factor (Types IIA and IIB) and Its Inhibition by Monoclonal Antibodies that Block Receptor Binding. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1646298] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryWe have recently shown the existence of two distinct forms of botrocetin (one-chain and two-chain), and demonstrated that the two-chain species is approximately 30 times more active than the one-chain in promoting von Willebrand factor (vWF) binding to platelet glycoprotein (GP) Ib. The N-terminal sequence of two-chain botrocetin is highly homologous to sea-urchin Echinoidin and other Ca2+-dependent lectins (Fujimura et al., Biochemistry 1991; 30: 1957–64).Present data indicate that purified two-chain botrocetin binds to vWF from plasmas of patients with type IIA or IIB von Willebrand disease and its interaction is indistinguishable from that with vWF from normal individuals. However, an “activated complex” formed between botrocetin and IIB vWF expresses an enhanced biological activity for binding to GP Ib whereas the complex with IIA vWF has a decreased binding activity. Among several anti-vWF monoclonal antibodies (MoAbs) which inhibit ristocetin-induced platelet aggregation and/or vWF binding to GPIb, only two MoAbs (NMC-4 and RFF-VIII RAG:1) abolished direct binding between purified botrocetin and vWF. This suggests that they recognize an epitope(s) on the vWF molecule in close proximity to the botrocetin binding site.
Collapse
Affiliation(s)
- Y Fujimura
- The Departments of Blood Transfusion and Pediatrics, Nara Medical College, Kashihara, Nara, Japan
| | - S Miyata
- The Departments of Blood Transfusion and Pediatrics, Nara Medical College, Kashihara, Nara, Japan
| | - S Nishida
- The Departments of Blood Transfusion and Pediatrics, Nara Medical College, Kashihara, Nara, Japan
| | - S Miura
- The Departments of Blood Transfusion and Pediatrics, Nara Medical College, Kashihara, Nara, Japan
| | - M Kaneda
- The Departments of Blood Transfusion and Pediatrics, Nara Medical College, Kashihara, Nara, Japan
| | - A Yoshioka
- The Departments of Blood Transfusion and Pediatrics, Nara Medical College, Kashihara, Nara, Japan
| | - H Fukui
- The Departments of Blood Transfusion and Pediatrics, Nara Medical College, Kashihara, Nara, Japan
| | - M Katayama
- The Takara-Shuzo Co, Ohtsu, Shiga, Japan
| | | | - Y Usami
- The Division of Biomedical Polymer Science, Fujita Health University School of Medicine, Toyoake, Aichi, Japan
| | - K Titani
- The Division of Biomedical Polymer Science, Fujita Health University School of Medicine, Toyoake, Aichi, Japan
| |
Collapse
|
46
|
Ohama R, Ohama Y, Yokoyama K, Miura S, Kawamura K, Shimodozono M. Rey-Osterrieth complex figure (ROCF) tracing task for evaluating unilateral spatial neglect. Ann Phys Rehabil Med 2018. [DOI: 10.1016/j.rehab.2018.05.174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
47
|
Koyama K, Saida Y, Abe T, Satokata M, Mishina Y, Sato K, Shoji S, Tanaka T, Nozaki K, Ichikawa K, Miyabayashi T, Ota T, Fujimori F, Ito R, Kondo R, Hiura T, Okajima M, Miura S, Watanabe S, Matsumoto N, Tanaka H, Kikuchi T. P2.03-015 Efficacy of EGFR-TKIs for EGFR Mutant NSCLC Patients with Central Nervous System Metastases: A Retrospective Analysis. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
48
|
Wakai N, Asakawa I, Tamamoto T, Morimoto Y, Yamaki K, Morimoto M, Miura S, Hasegawa M. Dosimetric Impact of Leaf Gap Error on Target Dose Using Volumetric Modulated Arc Therapy and Intensity-Modulated Radiation Therapy with Flattening Filter-Free Beam. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.2365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
49
|
Takahashi T, Asano Y, Yamashita T, Nakamura K, Saigusa R, Miura S, Ichimura Y, Toyama T, Hirabayashi M, Taniguchi T, Yoshizaki A, Sato S. A potential contribution of psoriasin to vascular and epithelial abnormalities and inflammation in systemic sclerosis. J Eur Acad Dermatol Venereol 2017; 32:291-297. [DOI: 10.1111/jdv.14459] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2017] [Accepted: 06/23/2017] [Indexed: 11/26/2022]
Affiliation(s)
- T. Takahashi
- Department of Dermatology; University of Tokyo Graduate School of Medicine; Tokyo Japan
| | - Y. Asano
- Department of Dermatology; University of Tokyo Graduate School of Medicine; Tokyo Japan
| | - T. Yamashita
- Department of Dermatology; University of Tokyo Graduate School of Medicine; Tokyo Japan
| | - K. Nakamura
- Department of Dermatology; University of Tokyo Graduate School of Medicine; Tokyo Japan
| | - R. Saigusa
- Department of Dermatology; University of Tokyo Graduate School of Medicine; Tokyo Japan
| | - S. Miura
- Department of Dermatology; University of Tokyo Graduate School of Medicine; Tokyo Japan
| | - Y. Ichimura
- Department of Dermatology; University of Tokyo Graduate School of Medicine; Tokyo Japan
| | - T. Toyama
- Department of Dermatology; University of Tokyo Graduate School of Medicine; Tokyo Japan
| | - M. Hirabayashi
- Department of Dermatology; University of Tokyo Graduate School of Medicine; Tokyo Japan
| | - T. Taniguchi
- Department of Dermatology; University of Tokyo Graduate School of Medicine; Tokyo Japan
| | - A. Yoshizaki
- Department of Dermatology; University of Tokyo Graduate School of Medicine; Tokyo Japan
| | - S. Sato
- Department of Dermatology; University of Tokyo Graduate School of Medicine; Tokyo Japan
| |
Collapse
|
50
|
Ohno Y, Koyama H, Lee HY, Miura S, Yoshikawa T, Sugimura K. Contrast-enhanced CT- and MRI-based perfusion assessment for pulmonary diseases: basics and clinical applications. Diagn Interv Radiol 2017; 22:407-21. [PMID: 27523813 DOI: 10.5152/dir.2016.16123] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Assessment of regional pulmonary perfusion as well as nodule and tumor perfusions in various pulmonary diseases are currently performed by means of nuclear medicine studies requiring radioactive macroaggregates, dual-energy computed tomography (CT), and dynamic first-pass contrast-enhanced perfusion CT techniques and unenhanced and dynamic first-pass contrast enhanced perfusion magnetic resonance imaging (MRI), as well as time-resolved three-dimensional or four-dimensional contrast-enhanced magnetic resonance angiography (MRA). Perfusion scintigraphy, single-photon emission tomography (SPECT) and SPECT fused with CT have been established as clinically available scintigraphic methods; however, they are limited by perfusion information with poor spatial resolution and other shortcomings. Although positron emission tomography with 15O water can measure absolute pulmonary perfusion, it requires a cyclotron for generation of a tracer with an extremely short half-life (2 min), and can only be performed for academic purposes. Therefore, clinicians are concentrating their efforts on the application of CT-based and MRI-based quantitative and qualitative perfusion assessment to various pulmonary diseases. This review article covers 1) the basics of dual-energy CT and dynamic first-pass contrast-enhanced perfusion CT techniques, 2) the basics of time-resolved contrast-enhanced MRA and dynamic first-pass contrast-enhanced perfusion MRI, and 3) clinical applications of contrast-enhanced CT- and MRI-based perfusion assessment for patients with pulmonary nodule, lung cancer, and pulmonary vascular diseases. We believe that these new techniques can be useful in routine clinical practice for not only thoracic oncology patients, but also patients with different pulmonary vascular diseases.
Collapse
Affiliation(s)
- Yoshiharu Ohno
- Division of Functional and Diagnostic Imaging Research, Department of Radiology and Advanced Biomedical Imaging Research Center, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
| | | | | | | | | | | |
Collapse
|